Key Highlights

  • Cumberland Pharmaceuticals shares closed down 21% at $6.69.
  • The company revised the schedule for its Phase 2 FIGHT DMD trial of ifetroban.
  • Long-term open-label extension safety and efficacy results, originally slated for August 2026, remain pending.
  • The update postpones insights into ifetroban's sustained impact on Duchenne muscular dystrophy-associated cardiomyopathy.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares closed down 21% at $6.69 after the company revised the schedule for its Phase 2 FIGHT DMD trial of ifetroban.

What Happened

The long-term open-label extension safety and efficacy results, originally slated for August 2026, remain pending and will be disclosed upon completion, postponing immediate insights into the drug's sustained impact on Duchenne muscular dystrophy-associated cardiomyopathy.

Market Reaction

Shares fell sharply as investors responded to the delay in data that had been expected this month, extending the timeline for a key readout in the ifetroban program.

Outlook

Completion of the long-term open-label extension phase of the FIGHT DMD trial represents the next disclosed milestone for ifetroban in Duchenne muscular dystrophy-associated cardiomyopathy.